Seeking collaboration- Addressing develop of small molecule antiviral therapeutics Horizon-HLTH-2027-01-DISEASE-05

R-Evolution Worldwide supports partners in building strong international consortia, identifying complementary expertise and developing competitive proposals aligned with Horizon Europe requirements and deadlines.

Experienced in EU-funded European and Euro-African projects, R-EvoWW provides hands-on support from proposal development and submission through project implementation, reporting and compliance, while fostering an efficient, collaborative and stimulating working environment.

What we offer:

• EU-funded project development, financial management and reporting

• Dissemination, communication and exploitation activities

• International consortium building and project coordination

What we are looking for:

• Virology and molecular characterisation of viruses with epidemic potential

• Discovery, screening and optimisation of small-molecule antiviral candidates

• Preclinical antiviral efficacy studies, including animal models, human organoids and organotypic systems

• Translational pharmacology, pharmacokinetics/pharmacodynamics (PK/PD) and antiviral resistance assessment

• Clinical infectious disease research and early-phase clinical trials

• Regulatory affairs and clinical development strategies for antiviral therapeutics

• Non-human primate (NHP) research expertise, where scientifically justified and required by regulators

• Medicinal chemistry, structure–activity relationship (SAR) studies and antiviral drug development

• GMP manufacturing, pharmaceutical formulation and CMC development

• Health technology assessment (HTA), market access and commercial exploitation of antiviral therapeutics